Sentence examples for an acceptable surrogate from inspiring English sources

It also proved an acceptable surrogate for biomechanical testing, confirming that a lateral lumbar interbody cage and plate construct reduces ROM to a similar degree as anterior lumbar interbody cage and plate constructs.

However, the Centers for Disease Control definition of central-line associated bloodstream infection (CLABSI) [17], which does not take catheter culture results into account, often is used as an acceptable surrogate.

Based on a series of meta-analyses of cohorts and clinical trials and simulations of trial designs and analytic methods, the workshop concluded that a confirmed decline in estimated GFR of 30% over 2 to 3 years may be an acceptable surrogate end point in some circumstances, but the pattern of treatment effects on GFR must be examined, specifically acute effects on estimated GFR.

Still, PPV should be an acceptable surrogate for stroke-volume variation in this type of comparison.

Blood pressure is therefore an acceptable surrogate outcome in preliminary short-term trials.

All patients, or an acceptable surrogate, provided informed consent to participate in the study.

Our analyses suggest that PFS is not a statistically acceptable surrogate endpoint for OS in patients with metastatic NSCLC treated in first line with docetaxel-based or vinorelbine-based chemotherapies.

Importantly, in a study using 86Y-DOTATOC PET as the gold standard for measuring renal residence times for 90Y-DOTATOC, Helisch and co-workers concluded that 111In-pentetreotide was a reasonable and acceptable surrogate for 90Y-DOTATOC when assessing individual patient pre-therapy renal dosimetry [35].

Product development for treatment of localized prostate cancer has been stymied by the impracticality of using overall survival as an endpoint in patients with localized disease and the lack of acceptable surrogate endpoints.

Thus, in this review we summarize all studies to date that measure cognitive function and both blood and bone lead levels (or acceptable surrogate for cumulative lead dose).

In these cases, measuring covariates that are closely connected (on drug disease cycle) to the clinical response may provide acceptable surrogate information for clinical decision making.